Related Experiment Video
Updated: Jun 8, 2026
13:56
Characterization of Molecular Mechanisms of In vivo UVR Induced Cataract
Published on: November 28, 2012
Targeting CYP450 modulation to decrease the risk of induced cataract in the experimental model
D V Patel1, T R Gandhi, K V Patel
1Department of Pharmacology, Anand Pharmacy College, SPU, Anand, India. dip_apc@yahoo.co.in
Indian Journal of Ophthalmology
|October 19, 2010
Summary
CYP450 enzyme modulation influences cataract development. Inhibitors delayed cataract onset, while inducers accelerated it, suggesting a role in cataract initiation.
Area of Science:
- Biochemistry
- Ophthalmology
- Pharmacology
Background:
- Diabetes mellitus is a primary risk factor for cataract formation.
- Certain diabetes medications modulate Cytochrome P450 (CYP450) enzymes, potentially impacting cataract risk.
Purpose of the Study:
- To investigate the influence of CYP450 modulation on galactose-induced cataract development.
- To assess the impact of CYP450 inhibitors and inducers on cataract initiation and progression.
Main Methods:
- Galactosemic cataract was induced in Sprague-Dawley rats.
- Rats were pretreated with a CYP450 inhibitor (nifedipine) or inducer (pioglitazone).
- Cataract progression and biochemical lens changes (CYP450 activity, proteins, glutathione) were analyzed.
Main Results:
- CYP450 inhibitor pretreatment delayed cataract occurrence; inducer pretreatment accelerated it compared to controls.
- CYP450 activity was significantly decreased by the inhibitor and increased by the inducer.
- Reduced glutathione levels remained unchanged, but total and soluble proteins increased.
Conclusions:
- CYP450 enzymes appear to play a role in the initiation of cataract.
- Modulation of CYP450 activity affects the onset of cataract but not its maturation pattern.
More Related Videos
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...